
Molecular Partners Investor Relations Material
Latest events

H1 2024
Molecular Partners
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Molecular Partners AG
Access all reports
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, canton of Zürich, Switzerland. Founded in 2004 by researchers from the University of Zürich, the company specializes in the development of a novel class of custom-built protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These DARPins are versatile and potent small-protein therapies with applications across various disease areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners has established itself in the biotechnology industry by leveraging its DARPin platform to create therapies that aim to surpass the limitations of current treatment options. Molecular Partners AG's shares are listed on the SIX Swiss Exchange and the Nasdaq.
Key slides for Molecular Partners AG


Corporate Presentation
Molecular Partners AG


Corporate Presentation
Molecular Partners AG
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
MOLN
Country
🇺🇸 United States